Recombinant ISRAA ameliorates imiquimod-induced psoriasis and knocking out Israa delays its onset.

Autor: Alsabbagh MM; Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain. ManahelAlsabbagh2014@alumnircsi.com., Aljishi M; Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain., Sultan A; Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain., Marwani AM; Animal Facility Unit, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain., Althaf N; Animal Facility Unit, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain., Bakhiet M; Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain., Taha S; Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain. SafaT@agu.edu.bh.
Jazyk: angličtina
Zdroj: Archives of dermatological research [Arch Dermatol Res] 2024 Oct 05; Vol. 316 (9), pp. 661. Date of Electronic Publication: 2024 Oct 05.
DOI: 10.1007/s00403-024-03410-5
Abstrakt: Psoriasis, an inflammatory disease, is largely mediated by T-helper 17 cytokines. We have previously identified the immune system-released activating agent (Israa) as a novel gene that connects the nervous and immune systems. This research aims to investigate the role of the Israa gene in psoriasis in vivo using the imiquimod-induced psoriasis model. We established the model in C57BL/6 wildtype mice, which were then treated with 200 pg/mouse, 400 pg/mouse, or 800 pg/mouse of recombinant ISRAA compared to methotrexate. Subsequently, we also induced psoriasis in Israa-knockout mice to confirm the effect of Israa. Results consistently showed improvement in psoriasis in all groups receiving recombinant ISRAA. The 200 pg/mouse dose eliminated the disease, reduced the cutaneous release of IL-17 to one-third and TNF-α to one-sixth, increased IL-10 release to over 500 pg, completely resolved parakeratosis, decreased epidermal thickness to one-half, and reduced the expression of CD4 and neutrophil elastase in the skin (all p < 0.05). Israa-knockout mice exhibited less severe psoriasis in all scoring, biochemical, and histological parameters compared to wild-type mice (p < 0.05). This study highlights Israa as a crucial molecule in psoriasis and confirms its immunomodulatory role in inflammatory diseases.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: